The mechanism of long-term B cell immunity against donor blood group antigens in recipients who undergo ABO-incompatible (ABOi) living-donor kidney transplantation (LKTx) is unknown. To address this question, we evaluated serial anti-A and anti-B antibody titers in 50 adult recipients. Donor-specific antibody titers remained low (≤1:4) in 42 recipients (84%). However, antibodies against nondonor blood group antigens were continuously produced in recipients with blood type O. We stimulated recipients' peripheral blood mononuclear cells in vitro to investigate whether B cells produced antibodies against donor blood group antigens in the absence of graft adsorption in vivo. Antibodies in cell culture supernatant were measured using specific enzyme-linked immunosorbent assays (ELISAs). Thirty-five healthy volunteers and 57 recipients who underwent ABOcompatible LKTx served as controls. Antibody production in vitro against donor blood group antigens by cells from ABOi LKTx patients was lower than in the control groups. Immunoglobulin deposits were undetectable in biopsies of grafts of eight recipients with low antibody titers (≤1:4) after ABOi LKTx. One patient with blood type A1 who received a second ABOi LKTx from a type B donor did not produce Bspecific antibodies. These findings suggest diminished donor-specific antibody production function in the setting of adult ABOi LKTx.
The mechanism of long-term B cell immunity against donor blood group antigens in recipients who undergo ABO-incompatible (ABOi) living-donor kidney transplantation (LKTx) is unknown. To address this question, we evaluated serial anti-A and anti-B antibody titers in 50 adult recipients. Donor-specific antibody titers remained low (≤1:4) in 42 recipients (84%). However, antibodies against nondonor blood group antigens were continuously produced in recipients with blood type O. We stimulated recipients' peripheral blood mononuclear cells in vitro to investigate whether B cells produced antibodies against donor blood group antigens in the absence of graft adsorption in vivo. Antibodies in cell culture supernatant were measured using specific enzyme-linked immunosorbent assays (ELISAs). Thirty-five healthy volunteers and 57 recipients who underwent ABOcompatible LKTx served as controls. Antibody production in vitro against donor blood group antigens by cells from ABOi LKTx patients was lower than in the control groups. Immunoglobulin deposits were undetectable in biopsies of grafts of eight recipients with low antibody titers (≤1:4) after ABOi LKTx. One patient with blood type A1 who received a second ABOi LKTx from a type B donor did not produce Bspecific antibodies. These findings suggest diminished donor-specific antibody production function in the setting of adult ABOi LKTx.
Introduction
ABO-incompatible (ABOi) transplantation is one of the strategies employed to overcome the shortage of donor organs. However, overcoming the production of serum antibodies against the donor's blood group A or B antigens by the recipient is the key factor to the success of this transplantation strategy (1) (2) (3) (4) (5) . Previous reports have shown that initial antibody titers against donor blood group antigens correlated well with the incidence of antibodymediated rejection (AMR) and graft survival (1) (2) (3) . Desensitization therapy using rituximab and plasmapheresis to decrease the titers of antibodies in ABOi living-donor kidney transplantation (LKTx) improves graft survival, which is not significantly different compared with ABOcompatible (ABOc) LKTx (6) (7) (8) (9) (10) . After applying desensitization therapy to ABOi LKTx, antibody titers against donor blood group antigens are less consistent with AMR (9) .
Despite the presence of antigens on the graft's vascular endothelium and the presence of antibodies in recipients' blood, clinical rejection does not always occur in ABOi LKTx (11, 12) . However, the mechanisms are undefined, and few studies address the long-term fate of antibodies against donor blood group antigens after ABOi LKTx (13, 14) . Here, we studied the B cell immunobiology of ABOi LKTx recipients and for the first time, to our knowledge, uncovered evidence of acquired donor-specific downregulation of antibody production function in both in vivo and in vitro experiments.
and laboratory information was extracted from electronic databases and patients' medical records. The Ethics Committee of the Faculty of Medicine of Niigata University approved this study, which was performed in accordance with the principles stated in the Declaration of Helsinki. Informed consent was obtained from all patients before participation in the study. Patients' characteristics are summarized in Table 1 . Recipients' blood types were A1, 19; B, 25; and O, 38. There were no A2 donors and recipients in this study. The median age of recipients was 39.0 years (range, 12-68), and 60 recipients (73.2%) were males. One-, 3-, 5-, and 10-year graft survival were 93%, 93%, 93%, and 73.8%, respectively. Patient selection in this study is shown in Figure 1 . Twenty out of 82 recipients were excluded from this study because 15 recipients were followed up in associated institutions and antibody titers were unrecorded in five recipients (early era). Serum isohemagglutinin antibody titers were followed with a median follow-up time of 3.4 years (range, 60-1920 days) in 50 recipients whose grafts survived. The other 12 recipients experienced loss of graft or graft function due to AMR (n = 3), chronic rejection (n = 5), recurrent nephritis (n = 2), malignancy (n = 1) and unknown reason (n = 1). For in vitro experiments, blood samples were collected from 30 recipients whose antibody titers maintained ≤1:4 in ABOi LKTx (Figure 1 ), 57 recipients who received ABOc LKTx and 35 healthy volunteers.
Immunosuppression and desensitization therapy for ABOincompatible LKTx
The protocol used in this study was similar to a recently published protocol (15) (16) (17) , as described in the supporting information. Briefly, current desensitization therapy consisting of a calcineurin inhibitor, methylprednisolone and mycophenolate mofetil is being performed for 28 days before ABOi LKTx. Since September 2004, two doses of rituximab were given on days À14 and À1 before transplantation instead of splenectomy. We typically performed antibody depletion with two sessions of doublefiltration plasmapheresis (DFPP) on days À5 and À2. After ABOi LKTx, basic induction and maintenance immunosuppression using a triple-drug regimen were used, similar to ABOc LKTx. DFPP and plasma exchange (PEX) were not performed after LKTx except for the cases of AMR.
Anti-ABO antibody isohemagglutinin antibody titers
Titration of anti-A and anti-B antibodies was performed using the test tube method, as described in the supporting information.
Cell isolation and cultures
Details of the assay are described in the supporting information. Peripheral blood mononuclear cells (PBMCs) were used for cell culture or flow cytometry. We cultured 5 
Flow cytometry
Details of the assay are described in the supporting information. Cells were stained with monoclonal antibodies (mAbs). Isotype-matched mouse mAbs were used as controls. To analyze the cell population, gating was set using whole PBMCs.
Enzyme-linked immunosorbent assay (ELISA) for anti-A and anti-B antibody
Details of the assay are described in the supporting information. ELISA plates were coated with 100 lL/well of 5 lg/mL of synthetic A-bovine serum albumin (BSA) (Dextra Laboratories, Reading, UK), synthetic B-BSA (Dextra Laboratories, Reading, UK) or control BSA (Roche Diagnostic, Indianapolis, IN). After the blocking procedure, diluted samples (1:10) were incubated in the plates for 2 h. The same standard serum samples pooled from type O volunteers were used in each assay. An antibody against A-BSA or B-BSA was detected using horseradish peroxidase-conjugated goat antihuman immunoglobulin g (IgG)/immunoglobulin m (IgM)-specific antibodies (Abs) (Southern Biotech, Birmingham, AL). Antigenantibody complexes were detected using 3,3 0 ,5,5 0 -tetramethylbenzidine liquid substrate (Sigma-Aldrich). Optical density (OD) was measured at 450 nm. The reaction of the samples against the wells coated with control BSA was used as background and subtracted from the gross OD of the sample. Samples from volunteer donors with blood type AB served as negative controls. According to the results in the negative controls, an absorbance score of >0.40, 0.40, 0.40 or 0.80 was considered positive for anti-A IgG, anti-A IgM, anti-B IgG, or anti-B IgM antibodies, respectively. Rejection due to antibody against donor ABO blood group antigen.
Immunofluorescence microscopy
Graft biopsies were acquired only when graft function deteriorated, indicated by an increase in the serum creatinine level or the development of proteinuria. Immunofluorescence microscopy was performed as previously described (18) and is described in detail in Data S1.
Cytokine assay
IL-10 and TGF-b1 levels were measured by ready-made ELISA using the multiple Ab sandwich principle (R&D Systems), as described in Data S1.
Statistical analysis
The statistical significance of differences in the data was evaluated using the nonparametric Mann-Whitney test and an unpaired or paired Student's t-test using SPSS software. The value of p ≤ 0.05 was considered to indicate statistical significance.
Results
Serum anti-A and anti-B isohemagglutinin antibody titers after ABO-incompatible LKTx Serum anti-A or anti-B antibody isohemagglutinin antibody titers were measured in 62 out of 82 recipients of ABOi LKTx (Figure 1 Table 2 ). The initial isohemagglutinin antibody titers against donor blood group antigens were relatively higher in the recipients who produced antidonor antibody ≥1:8 after ABOi LKTx ( Table 2 ).
The change of isohemagglutinin antibody titers in 50 recipients is shown in Figure 2 . Anti-A IgG and IgM antibody titers were persistently low after ABOi LKTx in A1?O recipients (Figures 2A and B (n=8)
In vitro experiment for the patients that the informed consents were obtained (Table 3) .
Patients whose antidonor blood type Ab ≤1:4 (Both IgG and IgM).
Lost graft function (n=12) Figure 1 : Retrospective cohort study of 82 consecutive recipients who underwent ABOi LKTx at Niigata University. Among all ABOi LKTx procedures performed between 1994 and 2014, 62 recipients whose anti-A or anti-B isohemagglutinin antibody titers could be examined after Tx were enrolled in this study. In vitro studies were performed using PBMCs from 30 recipients whose IgG and IgM antibody titers against donor blood group antigens were maintained at ≤1:4. ABOi, ABO-incompatible; LKTx, living-donor kidney transplantation; Tx, transplantation; PBMC, peripheral mononuclear cell.
level in these five recipients were not significantly different from the 50 ABOi LKTx recipients (data not shown). Two of these five recipients received rituximab and antibody depletion (DFPP) as well because of sensitization to the donor's HLA antigen. All five recipients received similar immunosuppressive therapy after ABOc LKTx as the recipients of ABOi LKTx. Anti-A and anti-B antibody titers remained unchanged after ABOc LKTx in these five recipients (Figures 2Q-T).
The isohemagglutinin antibody titers for the recipients who lost the graft are shown in Figure S1 . Three recipients underwent a graftectomy due to AMR within 10 days, and their serum antibody titers against the donor rapidly increased even though plasma exchange and additional immunosuppressive therapies were performed (case L1-3 in Figure S1 ). None of the three recipients had anti-HLA antibodies against donors before and after ABOi LKTx. One recipient lost the graft due to thrombotic microangiopathy (TMA) of an unknown cause. With the exception of these recipients, most of the recipients who lost the graft function due to recurrent nephritis, chronic rejection and malignancy had stable low antibody titers against the donor after ABOi LKTx.
Serum anti-Gal antibody levels after transplantation
To evaluate the functional capacity of producing antibodies in the recipients who were anti-A and anti-B antibody negative, we measured the antibody production to a thirdparty carbohydrate epitope Gal-a1-3b1-4GlcNAc-R (aGal), a major xenoantigen against which humans produce "natural" antibodies (19) . Figure 3 shows the levels of anti-Gal antibody in the recipients whose anti-A and anti-B antibody were negative (donor?recipient combination of A1?B, B?A1, A1B?A1, A1B?B and A1B?O) were not significant compared with the other recipients. Biopsy-proven rejection. 4 Median level at the last visit during follow-up period.
Assessment of antibody production in vitro
To exclude the effects of the absorption of anti-A or anti-B antibodies by the grafts in vivo, we cultured recipients' PBMCs in vitro and used ELISAs to measure antibody levels in culture supernatants. Among 50 recipients whose isohemagglutinin antibody titers were investigated, in vitro studies were performed for 30 recipients who received ABOi LKTx, and serum isohemagglutinin antibody titers (IgG and IgM) against donor blood group antigens remained ≤1:4 ( Figure 1 ). Fifty-seven recipients who received ABOc LKTx and 35 healthy volunteers served as controls for the in vitro assay. The characteristics of the recipients and volunteers for the in vitro study are shown in Table 3 . and "A?A"), respectively, tended to be lower than in healthy volunteers, although the difference was not significant ( Figure 5 ). These findings may be explained by systemic immunosuppression.
Anti-A antibody levels in cell cultures from recipients of ABOi type A or AB grafts were low, similar to "A?A" and "AB?AB" recipients, whereas anti-A antibody pre  -2  8  18  28  270  570  870  1170  1470  1770   B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O   pre  -2  8  18  28  270  570  870  1170  1470  1770   B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O   pre  -2  8  18  28  270  570  870  1170  1470  1770   B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O   pre  -2  8  18  28  270  570  870  1170  1470  1770   B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O  B→O   pre  -2  8  18  28  270  570  870  1170  1470  1770   A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O   pre  -2  8  18  28  270  570  870  1170  1470  1770   A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O   pre  -2  8  18  28  270  570  870  1170  1470  1770   A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O   pre  -2  8  18  28  270  570  870  1170  1470  1770   A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O  A1→O Biopsy-proven rejection. 4 Median level at the last visit during follow-up period.
patient was repeatedly exposed to type B antigens in the second ABOi LKTx, IgM and IgG antidonor antibodies (anti-B antibody) were not detected at all.
Comparison of recipients' B cell populations
Fluorescence activated cell sorter (FACS) analyses of the B cell populations are shown in Figure 6 . We analyzed the B cell subset according to previous reports (20) (21) (22) . The numbers of peripheral na€ ıve B cells (CD19+CD27À), memory B cells (CD19+CD27+), B-1 B cells (CD19+CD5+), plasmablasts (CD19+CD38+) and plasma cells (CD138+) were significantly higher in healthy volunteers than in transplant recipients. These findings may be explained by the use of immunosuppressive drugs.
Only the percentage of memory B cells was significantly lower in ABOi LKTx recipients than in ABOc LKTx recipients. After 7 days of in vitro culture, there was no significant difference between the B cell populations of ABOc or ABOi LKTx recipients, although the percentages of na€ ıve B cells, memory B cells and plasmablasts of healthy volunteers were higher than those of transplant recipients.
Serum IL-10 and TGF-b1 levels during stable graft function We collected serum samples from recipients who had experienced stable kidney graft function. The median serum IL-10 levels were 1.74 and 3.20 pg/mL in the ABOc and ABOi LKTx recipients, respectively ( Figure 7) . The median serum TGF-b1 levels were 425.6 and 1583.7 pg/mL in the ABOc and ABOi LKTx recipients, respectively ( Figure 7 ). Both cytokines were relatively higher in the ABOi LKTx recipients than in the ABOc LKTx recipients, even though the difference was not statistically significant.
Discussion
The present study demonstrated that the production of antibody against donor blood group antigen was specifically and significantly lower after the operation than before desensitization therapy in the majority of recipients who received ABOi LKTx and maintained good graft function. Many reports suggest that the immunobiological state after ABOi LKTx represents an accommodation through which rejection does not occur clinically despite the presence of antigens on the graft's vascular endothelium and the presence of antibodies in the blood of recipients (6, 7, 10, 11) . A number of intertwined factors are responsible, including ABO blood group antigens in the graft (18, 23) , antibody production (24, 25) , complement control (26) and immunosuppressive drugs (27) . However, the precise mechanisms of accommodation are still unknown. Although the characteristics of antibody production after ABOi LKTx are considered critical factors for AMR (1) (2) (3) (4) (5) reports describing the long-term B cell immunobiology after ABOi LKTx.
The present study demonstrates that 84% of recipients who received ABOi LKTx did not respond or showed a persistently diminished response against the red blood cells (RBCs) with the same donor blood group antigens, although recipients of type O continuously produced antibodies against nondonor blood group antigens. All recipients maintained the capacity to produce antibodies against the carbohydrate epitope Gal, which is similar to the ABO carbohydrate antigens. Five recipients (including two cases who received rituximab and DFPP) who underwent ABOc LKTx and received systemic immunosuppressive drugs similar to the ABOi LKTx recipients constantly produced antibodies against blood group antigens ( Figure 2 ). The desensitization therapy prior to ABOi LKTx was slightly modified; however, the phenomenon of a stable low antibody titer against the donor after ABOi LKTx was observed in most of our recipients, suggesting that immunosuppressive drugs and DFPP were not involved in donor-specific nonresponsiveness or hyporesponsiveness. Although B cells were stimulated in in vitro cultures in the absence of graft antigens, production of antibodies against donor blood group antigens was not detected in cell cultures from ABOi LKTx recipients, with a few exceptions. These findings suggest that the adsorption of antibodies by the kidney grafts in vivo did not account for donor-specific nonresponsiveness or hyporesponsiveness after ABOi LKTx. IgM antibodies against the donor by ELISA could be detected in supernatants of cultured cells from three ABOi LKTx recipients (patients 5, 9 and 20 in Table 4 ), even though their isohemagglutinin antibody titers were low. They had recurrent digestive tract infections, which might have resulted in IgM antibacterial antibody production that could have cross-reacted with the synthetic carbohydrate antigens of ELISA.
Three recipients had C4d deposition on PTCs, demonstrated by graft biopsies; however, the significance of this observation is unclear in ABOi LKTx (28) . Although C4d might have been deposited in early periods of ABOi LKTx due to antibodies, the half-life of covalently bound C4d is long (29) . In the present study, immunoglobulin deposits were undetected on the vascular endothelial cells of all recipients who underwent a biopsy. Therefore, the lectin pathway rather than the classical pathway might contribute to C4d deposition on PTCs in ABOi LKTx (30) . One patient never produced detectable titers of antibodies against donor blood group antigens, although he received a second challenge of antigens when he underwent a second ABOi LKTx. Taken together, these findings indicate that the majority of recipients who received ABOi LKTx acquired a downregulated antibody production function against donor blood group antigens.
The numbers of peripheral memory B cells in ABOi LKTx recipients were significantly lower than those in ABOc LKTx recipients, possibly due to rituximab therapy (31) or splenectomy (32) . However, the percentages of stimulated memory B cells in vitro and other B cell subsets were not significantly different between ABOc and ABOi LKTx recipients. Because ABOc LKTx recipients who received rituximab in the present study produced antibodies against type A and B blood group antigens (Figures 2Q-T) , rituximab administration or splenectomy was not the sole cause of donor-specific nonresponsiveness or hyporesponsiveness. The only significant difference between these recipients was the ABO incompatibility of their kidney grafts. Urschel et al (33) discussed in their report that contact with a large amount of T cell-independent antigens, such as the polysaccharide structure of Streptococcus pneumoniae and ABO carbohydrate antigens, may lead to downregulation of B cell function. Moreover, the persistence of donor antigens induces tolerance in models of transplantation that employ small or large animals (34, 35) . These findings suggest that the persistence of the graft involves donor-specific downregulation of B cell function in ABOi LKTx recipients. It is unknown whether depletion therapy of B cells before ABOi LKTx in addition to the existence of donor antigens is required for donor-specific downregulation of producing antibody against ABO carbohydrate antigens. To confirm whether the graft was necessary for donor-specific nonresponsiveness or hyporesponsivness in ABOi LKTx, we needed to see a rising antibody titer after graftectomy. However, there were no recipients with a donor-specific low antibody titer who underwent a graftectomy in this study.
Previously, immunologic analysis in ABOi heart transplantation (HTx) in infants demonstrated persistent deficiency of antibodies against the donor blood group as well as the absence of B cells with specific receptors for donor blood group antigens, together with demonstrable immunity to nondonor third-party blood group antigens (36, 37) . ABO carbohydrate antigens are classified as I-VI (38) . A recently published report showed that antibodies specific for A and/or B subtype II antigens-the only ABO antigen subtypes expressed in heart tissue (39)-were absent in infant ABOi HTx, demonstrating the fine specificity of B cell tolerance to donor/graft blood group antigens (40). Newborns do not produce natural antibodies to ABO antigens, with isohemagglutinin ontogeny generally beginning only after about 4 to 6 months of age (41) . This developmental lag allows infants to undergo safe ABOi HTx (37) . In contrast to infants, our recipients were adults who had developed antibodies reacting to ABO histoblood group antigens before ABOi LKTx. However, the present study showed persistently decreasing levels of antibodies to donor blood group antigens after ABOi LKTx. The antiinflammatory cytokines, IL-10 and TGF-b1, were relatively higher in ABOi LKTx recipients than in ABOc LKTx recipients, although the difference was not statistically significant. IL-10 and TGF-b1 are regulatory cytokines with pivotal functions in the control of inflammation. IL-10 regulates both innate and adaptive immunity to limit the magnitude of immune responses to microbial antigens, whereas TGF-b1 directly targets T cells to ensure immune tolerance to self-antigens and environmental antigens (42, 43) . Further examination is necessary to elucidate the nonresponsiveness or hyporesponsiveness against donor blood group antigens in adult ABOi LKTx.
Antibody titers are routinely measured using isohemagglutinin assays employing RBCs. However, ABO blood group antigens expressed on RBCs are not identical to those of the kidney due to different proteins linked to ABO carbohydrate antigens (18) . A recent report also demonstrates that the precursors of ABO carbohydrate antigens differ between RBCs and cardiac endothelial cells (39) . We show here that 8 out of 50 recipients who underwent ABOi LKTx produced antibodies continuously at titers ≥1:8 that reacted with RBCs of the same donor blood type. These recipients had high antibody titers before transplantation; however, those antibody titers decreased and did not recover to the pretransplant levels after ABOi LKTx. This immunological situation is referred to as accommodation. However, these antibodies, which were measured using isohemagglutinin assays after ABOi LKTx, may not react or are less reactive with endothelial cells in the kidney grafts due to the differences between blood group antigens of RBCs and kidneys. If so, these recipients might acquire donor-specific downregulation of producing antibodies induced specifically by the ABO antigens of the kidney grafts, which is similar to the majority of the recipients with very low antibody titers studied here.
In conclusion, donor-specific downregulation of the capability to produce antibodies was acquired in adult ABOi LKTx after stabilization of renal graft function. According to these results, nonresponsiveness or hyporesponsiveness against the donor in adult ABOi LKTx is persistently seen, which could possibly be explained by the existence of the ABOi graft as well as regulatory cytokines. Further investigation will be required to identify the mechanism that accounts for the success of ABOi LKTx.
Supporting Information
Additional Supporting Information may be found in the online version of this article.
Data S1: Supplemental materials and methods. Recipients L1, L2 and L3 underwent graftectomy due to antibody-mediated rejection on days 10, 9 and 10, respectively. Cases L4-8, L9, and L10-11 lost grafts or their graft function because of chronic rejection, malignancy and recurrent nephritis, respectively. Thrombotic microangiopathy (TMA) occurred for an unknown reason during surgery (on day 0) in case L12.
